Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.3606 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Ketone Beta-Hydroxybutyrate Supplement Retards the Loss of Glomerular Filtration Rate in Alport Mice on Dual RAS/SGLT2 Blockade.
Kidney360
March 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians-University, Munich, Germany.
Background: Several studies suggest that dietary beta hydroxybutyrate supplementation delays the progression of chronic kidney disease (CKD) by suppressing inflammation and fibrosis. We hypothesized that the oral supplementation with the beta-hydroxybutyrate (BHB) precursor 1,3-butanediol in addition to inhibitors of the renin-angiotensin system (RAS) and sodium-glucose transporter (SGLT)2 would be superior to dual RAS/SGLT2 blockade alone in attenuating the loss of glomerular filtration rate in Col4a3-deficient mice with Alport nephropathy, a spontaneous model of progressive CKD.
Methods: We performed a placebo-controlled study in Col4a3-deficient mice with Alport nephropathy.
Introduction: In 2021, finerenone - a novel, selective non-steroidal mineralocorticoid receptor antagonist - was approved in the US to treat adults with CKD and T2D This study aimed to describe characteristics and short-term outcomes of patients prescribed finerenone since regulatory approval.
Methods: This was a retrospective cohort study using claims and electronic health records data from the OM1 Real-World Data Cloud™. A total of 15,948 US adults with a previous diagnosis of chronic kidney disease (CKD) and type 2 diabetes who initiated 10mg or 20mg finerenone between July 2021 and August 2023 were included.
Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives.
J Clin Med
January 2025
Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon.
Diabetic Kidney Disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Among individuals with type 1 diabetes mellitus (T1DM), 30-40% are at risk of developing DKD. This review focuses on the mechanistic processes, available and emerging biomarkers for diagnosing, monitoring, and preventing DKD, as well as treatment options targeted at DKD patients.
View Article and Find Full Text PDFFinerenone in the management of diabetes kidney disease.
BMC Nephrol
February 2025
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!